



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : Mr. R. Vanlalruata, Assistant Director (F and D)
OFFICE OF CHIEF MEDICAL OFFICER,,
AIZAWL, MIZORAM, PIN:-796017.
- Serial No. and date of Inspector's memorandum : 05/IPA-AZL E/II-2025 , 16-APR-2025
- Number of Sample : NIL
- Date of receipt : 22-APR-2025
- Names of drugs purporting to be contained in the sample : Telmisartan and Hydrochlorothiazide Tablets IP
(Tellme-40H)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/0529	GUW/LS/2025-26/542	TL-23300	Dec-2023 Nov-2025	NA	Horizon Biocentials Pvt. Ltd., Plot No. 3 & 3A, Industrial Area, Trilokpur Road, Kala Amb, Distt. Sirmour (HP) -173030.

- Condition of seals on : Seals were intact & identical to the
[the packet or on portion of sample or container] specimen impression of the seal received
from Drugs Inspector

- Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 14-May-2025 To 01-Jul-2025

COMPOSITION : Each uncoated tablet contains: Telmisartan IP 40 mg Hydrochlorothiazide IP
12.5 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	Orange colored and off white (bi layered), round, bi-convex, uncoated tablets, in blister pack.	NA
2	Identification	Gives positive test for Telmisartan and Hydrochlorothiazide.	NA
3	Average weight	0.2383 gm	NA
4	Uniformity of weight	Complies.	+7.5 % of Average weight
5	Dissolution (for Telmisartan)	Passes the test.	NLT 80 % of claim
6	Dissolution (For Hydrochlorothiazide)	Passes the test.	NLT 80 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Telmisartan	40.3 mg/Tablet	40 mg/Tablet	100.75	95 % to 105 %	I.P. 2022
2	Hydrochlorothiazide	12.7 mg/Tablet	12.5 mg/Tablet	101.6	90 % to 107.5 %	I.P. 2022

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 05-AUG-2025

Rinku Kalita
GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

-----END OF REPORT-----

